X

Trial Profile

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apalutamide (Primary) ; Goserelin; Leuprorelin; LHRH receptor agonists; Triptorelin
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Sponsors Aragon Pharmaceuticals; Johnson & Johnson

Most Recent Events

15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium.
01 Oct 2019 Status changed from active, no longer recruiting to completed.
06 Apr 2018 Planned End Date changed from 31 Jan 2020 to 31 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com